Pretreatment Platelet-to-lymphocyte Ratio (PLR) As a Predictor of Response to First-line Platinum-based Chemotherapy and Prognosis for Patients with Non-small Cell Lung Cancer

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2014 Jan 11

PMID 24409356

Citations 50

Authors

Hongbing Liu

Ying Wu

Zhaofeng Wang

Yanwen Yao

Fangfang Chen

He Zhang

Yunfen Wang

Yong Song

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies showed the platelet-to-lymphocyte ratio (PLR) was associated with the prognosis of many tumors. However, to our knowledge, no study has explained the role of PLR in predicting response to first-line chemotherapy and prognosis for patients with non-small cell lung cancer (NSCLC). The aim of this study was to characterize the role of pretreatment PLR in NSCLC.

Methods: We consecutively enrolled 210 patients who were diagnosed with NSCLC in Jinling hospital (Nanjing, China) between January 2001 and August 2012. The platelet and lymphocyte counts of peripheral blood were measured before treatment was initiated. Each patient received at least two cycles of standardized combination chemotherapy. The response to chemotherapy was assessed after two cycles.

Results: Based on a receiver operator characteristic (ROC) curve, 152.6 was defined as the cut-off value of PLR for predicting response. An evaluated PLR (≥152.6) was an independent risk factor for response to first-line chemotherapy [odds ratio (OR), 4.503; 95% confidence interval (CI): 2.213-9.166, P=0.000]. Univariate and multivariate survival analyses showed that an elevated PLR was associated with a poor prognosis for patients with NSCLC [hazard ratio (HR), 1.867; 95% CI: 1.328-2.625; HR, 2.025; 95% CI: 1.405-2.919, respectively].

Conclusions: Our study shows that PLR maybe a potentially useful biomarker for predicting response to first-line chemotherapy and prognosis in NSCLC.

Citing Articles

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations.

Cooper R, Ramaswami D, Thomas J, Nieva J, Hsu R Discov Oncol. 2024; 15(1):689.

PMID: 39570469 PMC: 11582238. DOI: 10.1007/s12672-024-01606-9.

Clinical diagnostic value of methylated SEPT9 combined with NLR, PLR and LMR in colorectal cancer.

Huang M, Deng S, Li M, Yang Z, Guo J, Deng Y BMC Gastroenterol. 2024; 24(1):240.

PMID: 39075402 PMC: 11287835. DOI: 10.1186/s12876-024-03332-6.

Serum inflammatory markers as prognostic marker for nasopharyngeal carcinoma with liver metastasis: a multi-center retrospective study.

Saboorifar H, Zafarani Y, Gholampour G, Roghani A, Qiu F, Dequaniter D Eur Arch Otorhinolaryngol. 2024; 281(8):4315-4324.

PMID: 38642085 DOI: 10.1007/s00405-024-08649-2.

Multimodal treatment of oligometastatic non-small cell lung cancer.

Graca L, Pego A, Lareiro S, Pancas R BMJ Case Rep. 2023; 16(12).

PMID: 38061851 PMC: 10711880. DOI: 10.1136/bcr-2023-256097.

Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis.

Wang Y, Xu C, Zhang Z BMC Med. 2023; 21(1):486.

PMID: 38053096 PMC: 10696791. DOI: 10.1186/s12916-023-03199-6.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, ZAMORA E . Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012; 14(11):864-9. DOI: 10.1007/s12094-012-0872-5. View

Ramalingam S, Belani C . Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008; 13 Suppl 1:5-13. DOI: 10.1634/theoncologist.13-S1-5. View

Fathi A, Brahmer J . Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008; 20(3):210-6. DOI: 10.1053/j.semtcvs.2008.09.002. View

Smith R, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos J . Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008; 12(8):1422-8. DOI: 10.1007/s11605-008-0554-3. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T . Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012; 23(4):265-73. PMC: 3469862. DOI: 10.3802/jgo.2012.23.4.265. View

10.

Asher V, Lee J, Innamaa A, Bali A . Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011; 13(7):499-503. DOI: 10.1007/s12094-011-0687-9. View

11.

Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S . Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013; 30(1):432. DOI: 10.1007/s12032-012-0432-4. View

12.

Yao Y, Yuan D, Liu H, Gu X, Song Y . Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2012; 62(3):471-9. PMC: 11028855. DOI: 10.1007/s00262-012-1347-9. View

13.

Bhatti I, Peacock O, Lloyd G, Larvin M, Hall R . Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010; 200(2):197-203. DOI: 10.1016/j.amjsurg.2009.08.041. View

14.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

15.

Smith R, Bosonnet L, Raraty M, Sutton R, Neoptolemos J, Campbell F . Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2008; 197(4):466-72. DOI: 10.1016/j.amjsurg.2007.12.057. View

16.

Liu H, Gu X, Ma X, Lv T, Wu Y, Xiao Y . Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. Neoplasma. 2012; 60(2):203-8. DOI: 10.4149/neo_2013_027. View

17.

Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H . Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol. 2007; 2(5):402-7. DOI: 10.1097/01.JTO.0000268673.95119.c7. View

18.

He W, Yin C, Guo G, Jiang C, Wang F, Qiu H . Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013; 30(1):439. DOI: 10.1007/s12032-012-0439-x. View

19.

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

20.

Wakelee H, Bernardo P, Johnson D, Schiller J . Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006; 106(10):2208-17. DOI: 10.1002/cncr.21869. View